Home / Eliminating Disparities / Eliminating Precision Medicine Disparities Overview

Eliminating Precision Medicine Disparities Overview

Identification of actionable biomarkers continues to drive application of precision medicine in oncology. For patients with lung cancer, molecularly targeted therapies based on expression of specific biomarkers may be potential treatment options. Only through biomarker testing can clinicians discover whether lung cancers have targetable biomarkers.

Despite increasing evidence supporting the role of biomarkers in treatment decision-making for patients with lung cancer, recent studies1-3 report that more than 70 percent of patients treated in the community do not receive biomarker testing as recommended by National Comprehensive Cancer Network (NCCN) clinical practice guidelines, and more than 50 percent of patients do not receive appropriate precision medicine therapies based on the test results.2 Among underserved patient populations, the gap is even wider.4,5 Analysis of CMS claims data has revealed that Medicaid patients are 40 percent less likely to get tested than patients with private health insurance and Medicaid patients are 30 percent less likely to receive targeted therapies after testing, compared to patients with private health insurance.4

The ACCC Eliminating Precision Medicine Disparities project is focused on understanding specific barriers and challenges to equal access to precision medicine among underserved patient communities. Through this project, ACCC seeks to:

  • Evaluate patient and provider perceptions of equity in access to biomarker testing and gaps in access to appropriate precision medicine therapies based on identification of actionable biomarkers.
  • Gather feedback from patients and healthcare providers regarding specific barriers and challenges in obtaining biomarker testing and access to precision therapies.
  • Develop interventions for both patients and providers to promote biomarkers testing for patients with lung cancer in underserved communities.

The project is guided by an expert multidisciplinary Advisory Committee. ACCC is pleased to partner with LUNGevity for the patient-facing components of this education intervention.

For more information on this project, please contact the ACCC Provider Education department.

Video Podcast

[VIDEO PODCAST] Ep 09: Precision Medicine Disparities
Nov 11, 2021
Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC.

Christopher S. Lathan, MD, MS, MPH
Chief Clinical Access and Equity Officer
Dana-Farber Cancer Institute

Nikki Martin
Director of Precision Medicine Initiatives
LUNGevity Foundation

 

Featured Resource

Paying for Biomarker Testing

Paying-for-Biomarker-Testing-275x356A biomarker is a substance that doctors can measure in your tissues, blood, or other body fluids, like fluid around your lungs. Cells with certain biomarkers have errors (mutations) in their genes or changes in their protein levels that cause cells to divide in an uncontrolled way. This can cause lung cancer. It’s important to note that biomarker testing looks at your cancer’s cells and is not the same thing as genetic testing which looks for inherited changes to cells.

If biomarker testing shows that you are positive for a certain biomarker (positive means you have it), your doctor can choose treatments that work to attack the specific biomarker you have.
Download

 

Presentations & Abstracts

 

From Oncology Issues

v37n2-Biomarker-Testing-in-Patients-With-Non-Small-Cell-Lung-Cancer-60x60Biomarker Testing in Patients With Non-Small Cell Lung Cancer
Leigh M. Boehmer, PHARMD, BCOP; Upal Basu Roy, PHD, MPH; Janelle Schrag, MPH; Nikki Martin, MA; Alexandra Howson, PHD; Latha Shivakumar, PHD, CHCP; Brad Coleman, PMP; and Greg Salinas, PHD

While recent advances in precision medicine have substantially changed the management of lung cancer, care must be taken to ensure that these advances do not worsen health disparities. This study included a case component that divided overall respondents into two cohorts to observe how patient characteristics, such as age, socio-economic status, race/ethnicity, and health literacy, affected the likelihood of ordering biomarker testing.

v37n1-Patient-Perceptions-of-Biomarker-Testing-60x60Patient Perceptions of Biomarker Testing
Nikki Martin, MA; Lisa Dropkin; Lydia Redway; Mariel Molina; Janelle Schrag, MPH; Latha Shivakumar, PhD, CHCP; Leigh M. Boehmer, PharmD, BCOP; and Upal Basu Roy, PhD, MPH

As precision medicine becomes more common in the management of lung cancer, little is understood about the patient experience with biomarker testing, particularly of underserved patients. This study used survey and focus group methodology to determine patient perspectives on the educational needs within this community.

Appendix A: Patient Survey
Appendix B: Focus Group Guide

 

References

  1. Gutierrez ME, Choi K, Lanman RB, et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer. 2017;18(6):651-659.
  2. Mason C, Ellis PG, Lokay K, et al. Patterns of biomarker testing rates and appropriate use of targeted therapy in the first-line, metastatic non-small cell lung cancer treatment Setting. J Clin Pathw. 2018;(1):49–54.
  3. Audibert CM, Shea MB, Glass DJ, et al. Trends in the molecular diagnosis of lung cancer: results from an online market research survey. Washington, DC: Friends of Cancer Research; 2018.
  4. Palazzo LL, Sheehan DF, Tramontano AC, et al. Disparities and trends in genetic testing and erlotinib treatment among metastatic non-small cell lung cancer patients. Cancer Epidemiol Biomark Prev. 2019;28(5):926-934.
  5. Wong W, Wu N, et al. ALK testing trends and patterns among community practices in the United States. JCO Precis Oncol. 2018;2:1-11.

Our Partner


Our Supporters

Pfizer-200x80  

Funding & support provided by Janssen and Pfizer.